Award-Winning Publication on the Effects of Chemotherapeutics in an Animal Model Scientists from FDA’s National Center for Toxicological Research and Center for Drug Evaluation and Research, and the University of Arkansas for Medical Sciences have demonstrated that two commonly used chemotherapeutics (cyclophosphamide and doxorubicin), administered alone or in combination, did not induce behavioral alterations in a female-mouse model reflective of human breast-cancer patients. The study was designed to investigate the memory and attention problems that some female breast-cancer patients experience after chemotherapy – sometimes known as “chemo” brain. Thus, the selected chemotherapeutics were administered intravenously at clinically-relevant doses and the mice were assessed using a comprehensive test battery to detect effects on learning and memory, general activity, and motor coordination. The results of this study show no significant behavioral alterations and provide new insights into two commonly used chemotherapeutics. The lead author of the article —Timothy Flanigan, Ph.D. — was awarded the Developmental Neurotoxicology Society’s “2018 Richard Butcher New Investigator Award” for this publication. The article is available online at Toxicological Sciences
. For more information, contact Sherry Ferguson, Ph.D., Acting Director, Division of Neurotoxicology, FDA/NCTR
.png)
No hay comentarios:
Publicar un comentario